Comparative Pharmacology
Head-to-head clinical analysis: NALLPEN IN PLASTIC CONTAINER versus PROBAMPACIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NALLPEN IN PLASTIC CONTAINER versus PROBAMPACIN.
NALLPEN IN PLASTIC CONTAINER vs PROBAMPACIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nallpen is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically active against beta-lactamase-producing Staphylococcus aureus.
PROBAMPACIN is a synthetic aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, causing misreading of mRNA and preventing translocation of peptidyl-tRNA from the A-site to the P-site.
Nafcillin 1-2 g IV every 4 hours for moderate to severe infections; for MSSA bacteremia or endocarditis, 2 g IV every 4 hours.
100 mg IV every 12 hours over 30 minutes.
None Documented
None Documented
0.9-1.2 hours; prolonged in renal impairment (up to 7-10 hours in anuria); requires dose adjustment for CrCl <30 mL/min
4.5 hours (prolonged to 12-18 hours in severe renal impairment)
Primarily renal (60-80% unchanged drug via glomerular filtration and tubular secretion); biliary/fecal: minor (<5%)
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% other
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic